Literature DB >> 16510175

The racial disparity in outcomes in endometrial cancer: could this be explained on a molecular level?

V L Schimp1, R Ali-Fehmi, L A Solomon, A Hammoud, V Pansare, R T Morris, A R Munkarah.   

Abstract

OBJECTIVE: The racial disparities among patients with endometrial carcinoma have been previously reported. The objective of this study is to analyze and compare the molecular profiles in endometrial cancer in Caucasian and African American patients using a number of known molecular markers.
MATERIALS AND METHODS: 147 patients diagnosed with endometrial cancer between 1995 and 2001 were included in the study. Patients' demographics, clinical and pathological data were reviewed. Immunohistochemical staining for p53, VEGF, Ki-67 and HIF-1alpha was performed on tissue micro array sections. Tumors' expression of p53, VEGF, Ki-67, and HIF-1alpha was compared based on ethnicity and tumor type (Type I = endometrioid carcinomas and Type II = non-endometrioid carcinomas). Spearman's correlation and Fisher's Exact Tests were used for statistical analysis and Kaplan-Meier, log-rank and Cox regression were used for survival analysis.
RESULTS: 97 patients were Caucasian and 50 patients were African American. The mean age was 62 (33-91) years for Caucasian patients and 63.5 (24-89) years for the African American patients. African American patients had more Type II carcinoma than Caucasian patients (P = 0.055). High p53 expression was statistically significant among the African American patients (49% vs. 30%, P = 0.035) versus Caucasian patients. There was no significant difference demonstrated when comparing the VEGF, Ki-67, and HIF-1alpha expression between the racial groups. Survival analysis showed a trend toward a shorter survival in the African American patients compared to the Caucasian patients; median survival 62 versus 77 months (P = 0.061). On the other hand, we did not find a significant difference in survival by ethnicity when we adjusted for tumor histology.
CONCLUSION: While African American patients with endometrial cancer seem to show a trend toward a shorter survival, this seems to be mainly due to the fact that they have a higher proportion of Type II tumors. The molecular profiles for p53, Ki-67, VEGF and HIF-1alpha expression of histologically matched tumors were similar between the two ethnic groups.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16510175     DOI: 10.1016/j.ygyno.2006.01.041

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  7 in total

1.  Cadherins, catenins and cell cycle regulators: impact on survival in a Gynecologic Oncology Group phase II endometrial cancer trial.

Authors:  Meenakshi Singh; Kathleen M Darcy; William E Brady; Rashna Clubwala; Zachary Weber; Jon V Rittenbach; Ali Akalin; Charles W Whitney; Richard Zaino; Nilsa C Ramirez; Kimberly K Leslie
Journal:  Gynecol Oncol       Date:  2011-08-03       Impact factor: 5.482

Review 2.  Gynecologic cancer disparities: a report from the Health Disparities Taskforce of the Society of Gynecologic Oncology.

Authors:  Yvonne Collins; Kevin Holcomb; Eloise Chapman-Davis; Dineo Khabele; John H Farley
Journal:  Gynecol Oncol       Date:  2014-01-07       Impact factor: 5.482

3.  Physical activity and risk of endometrial adenocarcinoma in the Nurses' Health Study.

Authors:  Mengmeng Du; Peter Kraft; A Heather Eliassen; Edward Giovannucci; Susan E Hankinson; Immaculata De Vivo
Journal:  Int J Cancer       Date:  2013-11-29       Impact factor: 7.396

4.  Hypoxia-inducible factor-1 as a therapeutic target in endometrial cancer management.

Authors:  Laura M S Seeber; Ronald P Zweemer; René H M Verheijen; Paul J van Diest
Journal:  Obstet Gynecol Int       Date:  2010-02-14

5.  Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin.

Authors:  Zoya Yurkovetsky; Shlomo Ta'asan; Steve Skates; Alex Rand; Aleksey Lomakin; Faina Linkov; Adele Marrangoni; Lyudmila Velikokhatnaya; Matthew Winans; Elieser Gorelik; G Larry Maxwell; Karen Lu; Anna Lokshin
Journal:  Gynecol Oncol       Date:  2007-07-19       Impact factor: 5.482

6.  [Characteristic and clinical significance of microRNA expression between 144 Uygur and Han women with endometrial carcinoma].

Authors:  X Wang; D He; W T Li; S Adila; R Han; Y Dong
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2020-06-18

7.  A Delay from Diagnosis to Treatment Is Associated with a Decreased Overall Survival for Patients with Endometrial Cancer.

Authors:  Darren Dolly; Andreea Mihai; B J Rimel; Louis Fogg; Jacob Rotmensch; Alfred Guirguis; Edgardo Yordan; Summer Dewdney
Journal:  Front Oncol       Date:  2016-02-12       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.